Gapping up
In reaction to strong earnings/guidance: INTC +6.9%.
M&A news: OPEN +13.1% prior to halt (will be acquired by Priceline (PCLN) for $103/share), CGG +7.8% (hearing BHI for CGG speculation as catalyst), PCLN +0.7% (acuiring OPEN for $103/share).
Select INTC peers/related names showing strength: AMD +2.3%, HPQ +1.7%, MSFT +1.3%, MSFT +1.3%, NVDA +0.9%.
Select OPEN peers trading higher: LIVE +14.7%, YELP +11.9%, GRPN +11.3%, GRUB +8.6%.
Select oil/gas related names showing strength: CEO +2.3%, SDRL +1.5%, RDS.A +1.1%, BP +1.1%, STO +0.9%, APA +0.9%, SNP +0.8%, TOT +0.5%.
Other news: ICLD +18.9% (announces it has become a VMware (VMW) partner and the opening of a New England Sales Office), NKTR +7.7% (Nektar Therapeutics confirms U.S. FDA advisory committee recommends no cardiovascular outcomes trial for peripherally-acting mu-opioid receptor antagonist (pamora) class including movantik), ARO +4.8% (higher following Sycamore Partners expressing interest in acquire Express), NEPT +4.1% (Sherbrooke plant to resume production), FCSC +4% (receives orphan drug designation for genetically-modified autologous human fibroblasts to advance treatment development for recessive dystrophic epidermolysis bullosa), BOTA +3.6% (CEO & President Russel Plumb purchases approx 32K shares at an avg price of $2.99; EVP, Corporate Dev & Strategies Jopseph Patti purchases approx 14K shares- Form 4 Filings, YGE +3.3% (Malaysia's largest operational solar power plant powered by over 10 MWs of Yingli Solar modules), P +3% (still checking), CHSP +2.2% (to replace JOSB in the S&P SmallCap 600), BOBE +1.9% (featured on Mad Money), XEC +1.6% (to replace IGT in the S&P 500), LGND +1.3% (partner GSK announces results of Phase 3 PETIT2 study of Eltrombopag ), BTG +1.1% (announces Otjikoto Project Update; additional high grade drill results from the Wolfshag Zone).
Analyst comments: BRC +4.9% (upgraded to Buy from Underperform at BofA/Merrill), FIO +3.3% (initiated with a Buy at ROTH Capital), NMBL +3.3% (upgraded to Strong Buy at Raymond James), MNKD +2.2% (initiated with Outperform and $16 tgt at RBC Capital Mkts), PVA +2% (upgraded to Buy from Hold at Stifel), SRCL +1.9% (upgraded to Outperform at Robert W. Baird), CMCM+1.6% (initiated with Outperform at OPCO), EDR +1% (upgraded to Buy from Neutral at BofA/Merrill)
In reaction to strong earnings/guidance: INTC +6.9%.
M&A news: OPEN +13.1% prior to halt (will be acquired by Priceline (PCLN) for $103/share), CGG +7.8% (hearing BHI for CGG speculation as catalyst), PCLN +0.7% (acuiring OPEN for $103/share).
Select INTC peers/related names showing strength: AMD +2.3%, HPQ +1.7%, MSFT +1.3%, MSFT +1.3%, NVDA +0.9%.
Select OPEN peers trading higher: LIVE +14.7%, YELP +11.9%, GRPN +11.3%, GRUB +8.6%.
Select oil/gas related names showing strength: CEO +2.3%, SDRL +1.5%, RDS.A +1.1%, BP +1.1%, STO +0.9%, APA +0.9%, SNP +0.8%, TOT +0.5%.
Other news: ICLD +18.9% (announces it has become a VMware (VMW) partner and the opening of a New England Sales Office), NKTR +7.7% (Nektar Therapeutics confirms U.S. FDA advisory committee recommends no cardiovascular outcomes trial for peripherally-acting mu-opioid receptor antagonist (pamora) class including movantik), ARO +4.8% (higher following Sycamore Partners expressing interest in acquire Express), NEPT +4.1% (Sherbrooke plant to resume production), FCSC +4% (receives orphan drug designation for genetically-modified autologous human fibroblasts to advance treatment development for recessive dystrophic epidermolysis bullosa), BOTA +3.6% (CEO & President Russel Plumb purchases approx 32K shares at an avg price of $2.99; EVP, Corporate Dev & Strategies Jopseph Patti purchases approx 14K shares- Form 4 Filings, YGE +3.3% (Malaysia's largest operational solar power plant powered by over 10 MWs of Yingli Solar modules), P +3% (still checking), CHSP +2.2% (to replace JOSB in the S&P SmallCap 600), BOBE +1.9% (featured on Mad Money), XEC +1.6% (to replace IGT in the S&P 500), LGND +1.3% (partner GSK announces results of Phase 3 PETIT2 study of Eltrombopag ), BTG +1.1% (announces Otjikoto Project Update; additional high grade drill results from the Wolfshag Zone).
Analyst comments: BRC +4.9% (upgraded to Buy from Underperform at BofA/Merrill), FIO +3.3% (initiated with a Buy at ROTH Capital), NMBL +3.3% (upgraded to Strong Buy at Raymond James), MNKD +2.2% (initiated with Outperform and $16 tgt at RBC Capital Mkts), PVA +2% (upgraded to Buy from Hold at Stifel), SRCL +1.9% (upgraded to Outperform at Robert W. Baird), CMCM+1.6% (initiated with Outperform at OPCO), EDR +1% (upgraded to Buy from Neutral at BofA/Merrill)